By 2 hours after dosing, the percentage of patients without photophobia, among those who had photophobia at baseline was significantly greater for the SPr group than for the SP group (15.0% vs 27.2%, P = .029). Similarly,
the proportion of subjects without phonophobia in the SPr group was significantly greater than that in the SP group by hour 2 (11.3% vs 28.1%, P = .002). Statistically significant difference was found between SPr and SP treatment with respect to relieving nausea of migraine attack (Table 2). There were no serious drug-related AEs during the study period. Most AEs were mild or moderate in intensity. Thirty-four subjects in the SPr group reported somnolence (32.2%) and EPS (4.3%), with significant difference compared with the SP group. Among subjects assigned to SP treatment, 8 patients reported nausea 4 hours after see more dosing compared with 1 patient in SPr group. A list of all reported AEs is shown in Table 3. Headaches in adults are common neurological disorders and represent a considerable portion of patients seen in neurology clinics. Migraines are a type of primary headache and neurovascular disorder characterized by episodes of attacks accompanied by several combinations of gastrointestinal R788 molecular weight symptoms, autonomic nervous
system dysfunction, and an aura (transient neurologic symptoms) in some migraineurs.[2, 24] Recent progress in comprehension of migraine mechanisms has resulted in development of various pharmacotherapeutic options. Previous studies have revealed the efficacy of combination therapies in
the treatment of migraine attacks influencing both the presentation and the management of pain.25-27 In this randomized, double-blind, placebo-controlled trial, sumatriptan tablets (50 mg) and promethazine (25 mg) were found to be significantly more effective than sumatriptan (50 mg) plus placebo for the management of patients with migraine headache, as defined by modified IHS criteria. The intervention was employed for both genders, a wide range of age, and both types of migraine attacks (with and without aura). Accordingly, the majority of migraineurs with moderate to severe headache would benefit from using the 上海皓元医药股份有限公司 suggested pharmaceutical management. The result was demonstrated for the primary efficacy outcome (headache free) and for several secondary efficacy variables including headache intensity reduction, relief of associated symptoms, use of second dose and rescue medication, and rate of recurrence and AEs. The primary outcome of the trial was complete headache free at 2 hours after treatment. The IHS Committee on Therapeutics recommended 2-hour headache-free response as a more clinically relevant primary efficacy assessment for clinical trials of migraine medications.
Related posts:
- In accordance with that, we have conducted two studies to assess
- HRQL was similar in both groups regarding self-evaluation, wherea
- A good percentage of patients do improve even with
- P2X Receptor patients in the OPD group did not have a CR in the delayed period
- “
“Headache patients everywhere lost an ally and advocate re